Signs of broader recovery are emerging in the South Korean biotech sector following the landmark US approval of Yuhan Corporation's novel lung cancer drug Lazcluze (lazertinib) in August through licensee Johnson & Johnson.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?